Emory University is one of 12 institutions across the U.S. that will participate in a midstage clinical trial of CERE-110, an experimental gene therapy for Alzheimer's disease. The study will involve injecting the treatment in the brain of patients with mild to moderate Alzheimer's to stimulate brain cells to continuously produce nerve growth factor proteins.

Related Summaries